FDA panel to evaluate Sirion’s Durezol
FDA's Dermatologic Drugs Advisory Committee will meet May 29 to discuss Sirion Therapeutics' Durezol (difluprednate) for the treatment of inflammation and pain following ocular surgery. The NDA for the topical ophthalmic steroid has a June 26 action date...
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.